Metal Ion and Antibiotic Co-loaded Nanoparticles for Combating Methicillin-Rresistant Staphylococcus aureus-Induced...

Area of Science:

• Nanomedicine
• Infectious Diseases
• Biomaterials

Background:

• Osteomyelitis (OM) caused by methicillin-resistant Staphylococcus aureus (MRSA) poses a significant public health challenge due to antimicrobial resistance.
• Effective eradication of both extracellular and intracellular MRSA is crucial for successful OM treatment.

Purpose of the Study:

• To develop and characterize a novel zinc and vancomycin co-delivered nanotherapeutic (Man-Zn2+/Van NPs) for enhanced MRSA osteomyelitis treatment.
• To evaluate the efficacy of Man-Zn2+/Van NPs in targeting and eliminating MRSA, both in vitro and in vivo.

Main Methods:

• Fabrication and characterization of mannose-modified zinc and vancomycin co-delivered nanoparticles (Man-Zn2+/Van NPs).
• In vitro assessment of antibacterial activity against extracellular and intracellular MRSA, including minimum inhibitory concentration (MIC) determination.
• In vivo evaluation in a mouse osteomyelitis model to assess therapeutic efficacy, bone healing, and inflammatory response.

Main Results:

• Man-Zn2+/Van NPs demonstrated significant inhibitory activity against extra- and intracellular MRSA, reducing vancomycin's MIC.
• The nanoparticles showed efficient internalization by macrophages and targeted accumulation in infected bone tissue.
• In vivo studies confirmed a significant reduction in MRSA burden, improved gait, increased bone mass, and decreased inflammatory markers.

Conclusions:

• Mannose-mediated targeted delivery of zinc and vancomycin nanoparticles offers a potent strategy against MRSA osteomyelitis.
• This nanotherapeutic approach effectively combats both extracellular and intracellular MRSA, enhancing antibiotic sensitivity and promoting bone healing.
• Metal-antibiotic nanotherapeutics represent a promising avenue for addressing challenging resistant bacterial infections.